Management of hepatitis B: Summary of a clinical research workshop

By J. Hoofnagle, E. Doo, T. Liang, R. Fleischer, A. Lok. Hepatology, 2007

645 citations recorded by the source corpus.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/84285b600162b14f9ab2aa39dfab04180e66bb14

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. G. Dusheiko
2. X. Forns
3. J. Pawlotsky

In Hepatology

1. D. Moradpour
2. G. Dusheiko
3. X. Forns
4. J. Pawlotsky

Citations in the corpus

• Chronic hepatitis B: Update 2009 (2009, background): “Applied Environmental Microbiol 1976;32(4):572-574.”
• Update on Prevention, Diagnosis, and Treatment and of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance (2018, background): “The 20,000-IU/mL cutoff is an arbitrary value,((101)) which reflects the detection limit of historical non–polymerase chain reaction assays.”
• EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009, background): “(2) The ‘‘immune reactive phase” is characterized by HBeAg positivity, a lower level of replication (as reflected by lower serum HBV DNA levels), increased or fluctuating levels of aminotransferases, moderate or severe liver necroinflammation and more rapid progression of fibrosis compared to the pr”
• Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. (2008, neutral): “No 146 (83) 77 (86) 208 (83) 102 (82) Yes 30 (17) 13 (14) 42 ( 17 ) 23 (18)”
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. (2012, background): “(1) The ‘‘immune tolerant’’ phase is characterised by HBeAg positivity, high levels of HBV replication (reflected by high levels of serum HBV DNA), normal or low levels of aminotransferases, mild or no liver necroinflammation and no or slow progression of fibrosis [2,3,6,8].”
• Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update (2008, background): “Among the direct antiviral agents, telbivudine is classified as category B drug (no risk in animal studies, but unknown in human), whereas lamivudine, adefovir and entecavir are classified as category C drugs (teratogenic in animal, but unknown in human) by the US FDA [99].”